NGS-based proteomics platform with unprecedented depth.
Measurement of all forms of all proteins in all species.
High-Plex Proteomics
High-Plex proteomics works by translating information on specific protein abundance to information on specific DNA abundance. As such, High-Plex proteomics is succeeding by mimicking transcriptomics. All other existing High-Plex proteomics systems have been built from the bottom-up, by identifying probes for specific proteins one at a time and building an array of such probes.
At NeoVentures Biotechnology Europe we are the only ones to have taken a more powerful approach by working from the top-down. We have developed a platform based on the application of the same 268 million Aptamarkers to each sample. We characterize differential binding of these probes to potential biomarkers in biological fluids or tissues through next generation sequencing (NGS) analysis.
There are several advantages to our top-down approach:
- Greater depth of coverage 268 million probes versus several thousand with other platforms.
- Ease of use, we do not build arrays, and there is no need for specialized equipment to perform the Aptamarker analysis.
- High reproducibility, we are not using polyclonal antibodies.
- Capacity to characterize non-canonical in addition to canonical forms of proteins (post-translational modifications)
- Not limited by reference to human proteins.
- Clear path to Dx applications
Aptamarker Platform Workflow
Aptamarker Platform Applications
Preclinical patient stratification
Cross application from animal trials to humans.
Aptamarker are not subject to immune tolerance like antibodies. There will be higher number of orthologues across species.
Identification of new biomarkers and validation of existing ones
The discovery of new biomarkers is enabled by those Aptamarker frequency profiles that help explain the disease but are not correlated with existing biomarkers.
Assessment of treatment effect
Aptamarker structure patterns can predict outcomes from pre-treatment and treatment effects such as recovery and side effects. They be used as inclusion or exclusion criteria.
Drug development
The Aptamarker platform can elucidate different epitopes on target proteins. The loss of a set of structures for a specific epitope in the presence of treatment characterizes the binding site. Determine target kinetics, off-target binding, and patient to patient variance.
Our Vision
The Aptamarker platform has the potential to change the nature of health care. Our vision is to enable personalized medicine to a degree that has not been previously imagined. Personalized health care means personalized diagnosis. We are building a platform that will learn and improve with each additional individual analysed. This will require integration of artificial intelligence and automation. The ultimate goal is to observe the frequencies of everything in blood, to compare this to individual base levels and to determine when something is going wrong immediately as a result of changes. Our platform is the first that makes a future vision like this imaginable and feasible. We are looking for investors and partners who are committed to creating sustainable improvements to existing health care systems. The basis of such a system will be one that provides individuals with the tools and capacity to manage their own health and wellness.